United States: Northern District Of California Allows Securities Class Action Based On Alleged Price-Fixing To Proceed Against Pharmaceutical Wholesaler

On October 29, 2019, Judge Charles R. Breyer of the United States District Court for the Northern District of California denied a motion to dismiss a putative securities class action brought against a pharmaceutical wholesaler and two of its former executives.  Evanston Police Pension Fund v. McKesson Corp., et al., 18-cv-06525-CRB (N.D. Cal. Oct. 29, 2019).  Plaintiffs asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, alleging that defendants knew about and participated in a price-fixing conspiracy that allowed the company to profit from the inflated prices of generic drugs during the alleged class period and caused the company to suffer decreased earnings once reports revealed government investigations into alleged price-fixing and prices dropped.  The Court denied defendants’ motion to dismiss, holding that plaintiffs adequately alleged material misstatements, scienter, and loss causation at the pleading stage.

The Court first addressed plaintiffs’ allegations that defendants participated in or knew of a price-fixing conspiracy.  The Court held that plaintiffs failed to sufficiently plead direct evidence of defendants’ participation in an unlawful price-fixing agreement, noting that rather than pleading direct evidence of participation by defendants, plaintiffs merely pled “direct evidence of unlawful agreements among generic drug manufacturers” and that “the more plausible inference from this evidence is that [the company, a wholesaler,] was a victim of, not a participant in,” the price-fixing conspiracy.  Id. at *10.  The Court also found plaintiffs’ circumstantial-evidence allegations of “parallel conduct[] and five plus factors”—(1) actions against self-interest, (2) deviation from pre-collusion behavior, (3) state and federal investigations, (4) a market susceptible to collusion, and (5) participation in trade organizations—to be insufficient, relying on the Ninth Circuit’s rejection of “very similar plus factors” in In re Musical Instruments and Equipment Antitrust Litigation, 798 F.3d 1186, 1189-94 (9th Cir. 2015).  The Court did, however, find that plaintiffs adequately alleged that the company’s executives “were aware of price-fixing in the generic pharmaceutical industry when the challenged statements were made.”  Id. at *14.

The Court next considered six categories of statements plaintiffs alleged were made false or misleading based on defendants’ awareness of price-fixing in the generic pharmaceuticals industry, and it held that three of the categories could not be found to be false or misleading.

First, regarding defendants’ statements that the company “provided value to its pharmaceutical customers by obtaining competitive prices for generic drugs,” the Court found that such statements “were not rendered false by the manufacturers’ price-fixing conspiracy” and they “simply described the value of a wholesaler to independent pharmacies.”  Id. at *15.  Similarly, the Court found that statements by defendants that a generic-drug manufacturing subsidiary of the company was a “growth vehicle” were not false or misleading, because plaintiffs had “not sufficiently alleged [the subsidiary’s] participation in an unlawful conspiracy” and, therefore, “a general discussion of its growth and other merits would not be rendered misleading by failing to disclose other companies’ antitrust violations.”  Id. at *16.  The Court also rejected plaintiffs’ argument that a third category of statements that the company had “derisked its FY17 earnings from generics inflation” were false or misleading, finding such statements to be “essentially forward-looking” and, therefore, not actionable.  Id. at *17. 

The Court held, however, that three other categories of statements were actionable.  Statements that supply disruptions could increase prices were held to be actionable despite defendants’ arguments that, even if there were a price-fixing conspiracy, the company might still have faced a supply disruption which would increase prices and, indeed, that any illegal agreement between manufacturers limiting supply of drugs to the company would “technically be a supply disruption.”  Id. at *14-15.  The Court held instead that “[h]aving touted the good news that supply disruptions were leading to increased prices and thus increased profits,” defendants “had a duty to also disclose that some portion of its increased profits was actually [allegedly] due to far riskier and less sustainable unlawful agreements.”  Id. at *15.  The Court similarly found defendants’ statements describing the generic drug market as “competitive” were false or misleading, because “[c]laiming the generic drug market is competitive would be misleading if there was in fact widespread price fixing.”  Id. at *16.  Finally, the Court determined that certain statements by defendants attributing the company’s positive financial results to “legitimate market forces,” such as drug price increases, were false or misleading, because they “put generic drug price increases at issue, and therefore obligated [the company] to disclose the collusion helping to drive the inflation.”  Id. at *17. 

The Court next held that plaintiffs sufficiently alleged scienter under the “core operations” theory, pursuant to which the falsity of a statement may itself be “indicative of scienter where it is combined with allegations regarding a management’s role in the company that are particular and suggest that defendant had actual access to the disputed information, and where the nature of the relevant fact is of such prominence that it would be absurd to suggest that management was without knowledge of the matter.”  Id. at *19.  Based on the executive defendants’ “statements touting their knowledge of the generics market, combined with the magnitude of the price-fixing conspiracy, its significance to [the company’s] revenues, and the executive defendants’ roles at the company,” the Court held that the company and its top executives must have been aware that collusive behavior drove price inflation.  Id. at *18.  Had the company’s executives possessed the “intimate” knowledge of generic drug pricing and conditions in the market they claimed, the Court held, “it was at least deliberately reckless not to investigate the accuracy of their statements that price increases were being driven by specific, legitimate supply disruptions, rather than collusive activity.”  Id. at *19.  The Court also held that the “strong correlation between financial results and stock options or cash bonuses” for company executives supported an inference of scienter.  Id. at *21.

Finally, the Court determined that plaintiffs sufficiently alleged loss causation based on the company’s stock price drops when the purported corrective disclosures occurred.  As such, the Court thus denied the motion to dismiss.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions